InnoCare Pharma Limited Share Price
Stocks
9969
KYG4783B1032
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.10 HKD | +7.25% |
|
+5.21% | -9.76% |
| 06-05 | InnoCare Pharma Limited Announces Management Changes, Effective June 5, 2026 | CI |
| 06-05 | InnoCare Pharma Presents Phase IIb Study Results For Orelabrutinib In Systemic Lupus Erythematosus | CI |
| Market Cap | 19.98B 23.13B 2.95B 2.55B 2.35B 2.2B 4.12B 281B 4.19B 27.74B 10.82B 137B 11.08B 10.84B 473B | P/E Ratio 2026 * |
84.3x | P/E Ratio 2027 * | 92x |
|---|---|---|---|---|---|
| Enterprise Value | 13.96B 16.17B 2.06B 1.78B 1.64B 1.54B 2.88B 196B 2.93B 19.39B 7.56B 95.46B 7.74B 7.58B 331B | EV / Sales 2026 * |
5.98x | EV / Sales 2027 * | 4.73x |
| Free-Float |
67.83% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: InnoCare Pharma Limited
| 1 day | +7.25% | ||
| 1 week | +5.21% | ||
| Current month | -4.56% | ||
| 1 month | -14.62% | ||
| 3 months | -5.53% | ||
| 6 months | -22.21% | ||
| Current year | -9.76% |
| 1 week | 9.65 |  | 11.24 |
| 1 month | 9.65 | | 12.77 |
| Current year | 9.65 | | 16.04 |
| 1 year | 9.65 | | 20.62 |
| 3 years | 4.03 | | 20.62 |
| 5 years | 4.03 | | 32.05 |
| 10 years | 4.03 | | 32.05 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jisong Cui
CEO | Chief Executive Officer | 62 | 17/08/2016 |
Xin Fu
DFI | Director of Finance/CFO | 48 | 17/12/2023 |
John Zhou
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Yigong Shi
BRD | Director/Board Member | 58 | 27/11/2018 |
Kun-Liang Guan
BRD | Director/Board Member | 62 | 20/01/2025 |
Jisong Cui
CHM | Chairman | 62 | 26/09/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 14/07/25 | Buy | Director | 100,000 | 0.0384% | ||
| 14/07/25 | Buy | 125,000 | 0.0480% | |||
| 14/07/25 | Buy | Chief Executive Officer | 412,500 | 0.1585% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.25% | +5.21% | -22.70% | +51.02% | 2.95B | |
| +1.03% | +2.30% | +55.91% | +114.22% | 56.42B | |
| +2.72% | +3.26% | +46.05% | +44.91% | 44.54B | |
| +1.12% | +2.79% | -15.04% | -21.68% | 22.9B | |
| +1.17% | +3.85% | -0.89% | +403.86% | 21.21B | |
| +3.81% | -5.07% | +11.00% | -30.62% | 16.4B | |
| +0.15% | +2.24% | +9.32% | -39.30% | 15.4B | |
| -0.69% | +0.82% | +27.75% | +176.72% | 13.35B | |
| +5.27% | +5.54% | +19.65% | - | 12.36B | |
| +1.61% | +1.28% | +95.75% | +205.26% | 11.15B | |
| Average | +2.34% | +2.40% | +22.68% | +100.49% | 21.67B | |
| Weighted average by Cap. | +1.80% | +2.40% | +31.29% | +98.89% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.34B 2.7B 345M 298M 275M 257M 482M 32.8B 489M 3.24B 1.26B 15.96B 1.3B 1.27B 55.28B | 2.87B 3.32B 424M 366M 337M 316M 592M 40.28B 601M 3.98B 1.55B 19.6B 1.59B 1.56B 67.88B |
| Net income | 194M 225M 28.73M 24.82M 22.87M 21.41M 40.12M 2.73B 40.74M 270M 105M 1.33B 108M 106M 4.6B | 188M 218M 27.8M 24.01M 22.13M 20.71M 38.82M 2.64B 39.42M 261M 102M 1.29B 104M 102M 4.45B |
| Net Debt | -6.01B -6.97B -889M -768M -707M -662M -1.24B -84.49B -1.26B -8.35B -3.26B -41.12B -3.34B -3.26B -142B | -6.43B -7.44B -950M -820M -756M -708M -1.33B -90.28B -1.35B -8.93B -3.48B -43.94B -3.56B -3.49B -152B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/06/26 | 11.10 $ | +7.25% | 14,302,050 |
| 11/06/26 | 10.35 $ | -0.38% | 5,292,880 |
| 10/06/26 | 10.39 $ | +3.69% | 7,027,970 |
| 09/06/26 | 10.02 $ | -0.30% | 9,158,734 |
| 08/06/26 | 10.05 $ | -4.74% | 5,279,500 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 9969 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition